Mind Medicine Inc (NEOE:MMED)
C$ 14.9 1.29 (9.48%) Market Cap: 1.05 Bil Enterprise Value: 934.33 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 22/100

Q2 2024 Mind Medicine (MindMed) Inc Earnings Call Transcript

Aug 13, 2024 / 12:00PM GMT
Operator

Good morning, and welcome to the Mind Medicine second quarter 2024 financial results and corporate update conference call. (Operator Instructions) This call is being webcast live on the investors and media section of MindMed's website at mindmed.co, and a recording will be available after the call. I would now like to introduce Rob Barrow, CEO of MindMed. Please go ahead.

Robert Barrow;MindMed;Inc;Chief Executive Officer
Mind Medicine;Director

()- -

Thank you, and good morning, everyone. Welcome to our second quarter 2024 financial results and corporate update conference call. Today, we will be sharing highlights from the second quarter along with the significant progress we've made with plans for our Phase 3 program in generalized anxiety disorder, or GAD. Additionally, I'm excited to share further specifics about the expansion of our R&D program for MM120 into major depressive disorder or MDD, both of which are further supported by the financing we announced last week.

The press release

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot